middl
east
respiratori
syndrom
coronaviru
merscov
continu
caus
outbreak
human
result
spillov
event
dromedari
contrast
human
merscovexpos
dromedari
develop
mild
infect
except
potent
virusneutr
antibodi
respons
strong
antibodi
respons
may
caus
affin
matur
result
repeat
exposur
viru
fact
dromedariesapart
convent
antibodieshav
rel
uniqu
heavi
chainonli
antibodi
hcab
hcab
devoid
light
chain
long
complementaritydetermin
region
uniqu
epitop
bind
properti
allow
recogn
bind
high
affin
epitop
recogn
convent
vhh
nanobodi
vitro
vhh
effici
block
viru
entri
picomolar
concentr
select
vhh
bind
except
high
affin
receptor
bind
domain
viral
spike
protein
furthermor
camelhuman
chimer
hcabscompos
camel
vhh
link
human
fc
domain
lack
exonhad
extend
halflif
serum
protect
mice
lethal
merscov
challeng
hcab
repres
promis
altern
strategi
develop
novel
intervent
merscov
also
emerg
pathogen
novel
viru
term
middl
east
respiratori
syndrom
coronaviru
merscov
identifi
human
six
year
later
laboratoryconfirm
mer
case
includ
fatal
outcom
report
global
case
thu
far
origin
arabian
peninsula
result
hospit
outbreak
convinc
evid
dromedari
camel
primari
sourc
merscov
infect
human
viru
isol
camel
similar
isol
human
also
replic
human
cell
addit
epidemiolog
phylogenet
analys
suggest
multipl
introduct
merscov
human
popul
rais
great
concern
merscov
could
continu
caus
outbreak
near
futur
effect
prophylact
therapeut
intervent
strategi
therefor
need
combat
viru
monoclon
antibodi
mab
promis
candid
treatment
prevent
viral
infect
recent
merscovneutr
mab
identifi
character
sever
research
group
use
variou
approach
antibodi
isol
human
b
cell
memori
b
cell
merscovinfect
individu
transgen
mice
express
human
antibodi
variabl
heavi
chain
vhh
light
chain
mab
target
receptor
bind
domain
rbd
merscov
spike
protein
merscov
spike
protein
structur
viral
compon
contain
rbd
locat
subunit
protein
bind
merscov
entri
receptor
dipeptidyl
antibodi
rais
rbd
block
merscov
infect
vitro
potent
mab
identifi
merscov
thu
far
recogn
rbd
howev
product
mab
larg
scale
costli
requir
long
development
process
rel
larg
quantiti
might
need
protect
human
viral
infect
altern
antibodi
engin
technolog
allow
clone
variabl
region
mab
express
escherichia
coli
yeast
produc
larg
amount
recombin
antibodi
fragment
date
therapeut
mab
licens
chimer
antibodi
heavi
chainonli
antibodi
hcab
natur
produc
camelid
speci
antibodi
dimer
contain
light
chain
antigen
recognit
region
sole
form
vhh
region
term
singledomain
antibodi
fragment
fragment
kda
size
rel
stabl
produc
high
yield
prokaryot
system
camelid
vhh
long
complementaritydetermin
region
loop
capabl
bind
uniqu
epitop
access
convent
antibodi
benefici
properti
vhh
exploit
rang
biotechnolog
applic
includ
diagnost
therapeut
fundament
research
recent
preclin
success
vhh
block
von
willebrand
factormedi
platelet
aggreg
show
therapeut
potenti
vhh
may
also
effici
prevent
entri
virus
host
cell
chimer
hcab
camel
vhh
human
fc
portion
lack
exon
camel
hcab
allow
interact
human
effector
cell
complement
cascad
factor
sever
studi
demonstr
presenc
high
level
merscovspecif
neutral
antibodi
mean
viru
neutral
titer
dromedari
camel
middl
east
africa
therefor
next
human
mab
character
merscovneutr
vhh
dromedari
camel
could
serv
altern
strategi
develop
neutral
antibodi
report
identif
character
neutral
vhh
merscov
immun
dromedari
camel
demonstr
prophylact
activ
camelhuman
chimer
hcab
merscov
transgen
mous
model
first
identifi
merscovneutr
vhh
direct
clone
screen
vhh
complementari
dna
cdna
librari
deriv
bone
marrow
cell
given
high
frequenc
specif
plasma
cell
rather
use
b
cell
peripher
blood
immun
anim
fig
bone
marrow
obtain
two
dromedari
camel
immun
modifi
vaccinia
viru
encod
merscov
spike
protein
subsequ
challeng
live
merscov
time
sampl
merscovneutr
antibodi
detect
high
level
titer
sera
dromedari
fig
subsequ
vhhspecif
primer
use
amplifi
vhh
librari
bone
marrow
cdna
nest
polymeras
chain
reaction
pcr
fig
c
fig
schemat
overview
vhh
identif
direct
clone
use
bone
marrow
immun
dromedari
camel
immun
dromedari
camel
anesthet
bone
marrow
aspir
perform
total
rna
isol
firststrand
cdna
synthesi
vhh
gene
amplifi
clone
prokaryot
express
vector
transform
e
coli
individu
clone
grown
overnight
plate
express
vhh
periplasm
next
crude
vhh
releas
periplasm
freezethaw
bacteri
pellet
crude
vhh
use
immunofluoresc
stain
virusinfect
cell
immunofluoresc
posit
clone
character
genet
makeup
specif
potenc
sequenc
antigenspecif
enzymelink
immunosorb
assay
elisa
viru
neutral
assay
epitop
map
structur
analysi
final
potent
vhh
produc
camelhuman
chimer
singl
chainonli
antibodi
gel
purif
pcr
product
directli
clone
dephospho
rylat
prokaryot
express
vector
tag
vhh
six
histidin
amino
acid
c
terminu
obtain
highdivers
repertoir
vhh
reduc
number
amplif
cycl
ligat
vhh
plasmid
librari
transform
e
coli
strain
plate
ampicillin
nutrient
agar
plate
without
precultur
bacteria
nutrient
medium
total
vhh
clone
camel
camel
obtain
singl
transform
event
grown
individu
plate
periplasm
express
recombin
vhh
induc
fig
vhh
purifi
periplasm
crude
extract
express
verifi
use
sdspolyacrylamid
gel
electrophoresi
page
analysi
fig
next
use
formalinfix
permeabil
virusinfect
cell
either
merscovinfect
sever
acut
respiratori
syndrom
coronaviru
sarscov
infect
select
merscovspecif
vhh
use
immunofluoresc
stain
crude
periplasm
vhh
extract
incub
infect
cell
vhh
cell
bind
visual
fluoresc
label
antihistidin
antibodi
secondari
antibodi
vhh
clone
screen
confoc
microscopi
fig
obtain
merscovreact
vhh
camel
camel
none
react
sarscovinfect
cell
confirm
specif
vhh
merscov
randomli
select
sever
clone
doubl
stain
merscovinfect
cell
use
rabbit
antimerscov
serum
reveal
vhh
exclus
target
merscovinfect
cell
fig
test
whether
vhh
identifi
studi
recogn
rbd
part
perform
merscov
merscov
rbdspecif
elisa
merscovreact
vhh
direct
merscov
subunit
vhh
block
bind
recombin
merscov
receptor
present
cell
fig
vitro
block
vhh
direct
rbd
fig
next
select
block
vhh
character
vhh
clone
neg
immunofluoresc
stain
elisa
use
neg
control
use
merscov
plaqu
reduct
neutral
test
prnt
estim
viru
neutral
capac
vhh
except
control
test
vhh
inhibit
merscov
entri
vari
concentr
rang
pm
prnt
tabl
vhh
high
neutral
capac
select
character
obtain
sequenc
block
vhh
known
import
interact
antigen
assumpt
made
vhh
ident
would
recogn
epitop
overal
vhh
differ
sequenc
rang
length
amino
acid
fig
phylogenet
analysi
sequenc
reveal
consider
divers
among
differ
vhh
clone
show
select
vhh
form
differ
cluster
differ
sequenc
fig
sequenc
contain
characterist
vhh
tetrad
except
clone
amino
acid
posit
show
vh
characterist
valin
leucin
tryptophan
best
merscovneutr
vhh
differ
sequenc
fig
subsequ
best
four
neutral
vhh
control
select
largescal
product
purif
obtain
high
quantiti
mg
pure
histag
affinitypurifi
vhh
liter
bacteri
cultur
fig
mix
vhh
recombin
merscov
spike
protein
gener
vhhspike
complex
observ
nonreduc
page
analysi
fig
addit
equilibrium
dissoci
constant
k
vhh
spike
protein
four
vhh
rel
low
next
test
neutral
activ
vhh
vitro
prnt
four
vhh
confirm
neutral
merscov
high
effici
prnt
valu
rang
pm
inhibit
observ
use
control
high
concentr
fig
small
size
vhh
rapidli
clear
circul
therefor
addit
produc
four
vhh
camelhuman
chimer
hcab
ctermin
tag
vhh
fc
part
human
immunoglobulin
contain
hing
exon
fig
right
hcab
form
homodim
kda
size
exhibit
approxim
neutral
capac
monomer
vhh
vitro
fig
moreov
use
elisa
could
detect
hcab
bind
even
lower
concentr
pm
fig
map
vhh
bind
epitop
first
test
bind
four
differ
vhh
recombin
protein
use
fortebio
octet
system
shown
fig
four
vhh
compet
singl
epitop
subsequ
use
set
recombin
protein
contain
singl
amino
acid
mutat
present
spike
protein
merscov
field
isol
locat
within
receptor
bind
subdomain
residu
rbd
engag
merscov
polyclon
antibodi
irrelev
vhh
four
vhh
test
abil
bind
variant
merscov
polyclon
antibodi
control
bound
variant
fig
b
wherea
four
merscovspecif
vhh
bind
variant
differ
bind
variant
also
bind
variant
wherea
show
partial
bind
three
addit
variant
fig
c
f
data
show
four
vhh
bind
epitop
receptor
bind
subdomain
partial
overlap
consist
bind
competit
analysi
fig
rbd
residu
import
viru
bind
cellular
receptor
four
vhh
bind
variant
suggest
vhh
neutral
merscov
like
block
bind
cellular
receptor
despit
sever
attempt
abl
identifi
merscov
escap
variant
vitro
best
neutral
capac
epitop
recognit
select
vivo
test
test
prophylact
efficaci
vivo
use
transgen
mous
model
first
experi
mice
given
irrelev
vhh
control
per
mous
nine
mice
per
group
intraperiton
inject
hour
intranas
infect
lethal
dose
merscov
emc
isol
mice
receiv
lost
weight
die
within
day
postinocul
dpi
well
inject
control
vhh
fig
next
test
control
use
similar
experiment
setup
mice
treat
gain
weight
fig
mice
surviv
fig
contrast
control
group
lost
weight
die
within
dpi
fig
b
gross
patholog
chang
fig
mononuclear
cell
infiltr
alveolar
edema
fig
observ
lung
control
mice
day
inocul
wherea
low
dose
mice
partial
protect
basi
observ
reduct
patholog
abnorm
dpi
fig
lung
highdos
mice
show
patholog
chang
time
point
test
fig
addit
infecti
viru
could
isol
lung
mice
high
viral
titer
observ
low
doseand
control
hcabtreat
mice
fig
also
evalu
pharmacokinet
vhh
hcab
sera
mice
treat
either
first
estim
presenc
merscovneutr
activ
sera
obtain
day
treatment
neutral
viru
observ
sera
control
mice
fig
consist
report
rapid
clearanc
small
vhh
domain
circul
signific
level
neutral
antibodi
mean
titer
observ
sera
mice
treat
limit
extent
low
dosetr
mice
mean
titer
fig
second
test
presenc
circul
sera
obtain
variou
time
point
inject
day
treatment
elisa
shown
fig
vhh
small
size
high
stabil
solubl
affin
effici
recogn
antigen
mani
potenti
biomed
applic
includ
treatment
cancer
autoimmun
diseas
viru
infect
moreov
vhh
gain
much
attent
field
diagnost
therapeut
viral
diseas
use
detect
virus
marburg
viru
human
immunodefici
viru
hiv
influenza
viru
dengu
viru
noroviru
vhh
also
block
viru
attach
host
cell
respiratori
syncyti
viru
influenza
viru
hepat
b
viru
rotaviru
hiv
infect
vhh
inhibit
viral
rna
transcript
nuclear
import
viral
ribonucleoprotein
shown
merscovneutr
vhh
obtain
immun
dromedari
camel
natur
infect
dromedari
camel
remark
high
level
neutral
antibodi
merscov
use
dromedari
show
high
level
neutral
antibodi
sera
identifi
merscovneutr
vhh
direct
clone
vhh
cdna
librari
use
bone
marrow
major
sourc
highli
enrich
longliv
antibodyproduc
plasma
cell
immun
antigenstimul
b
cell
undergo
affin
matur
germin
center
secondari
lymphoid
organ
differenti
plasma
cell
secret
antibodi
signific
portion
longliv
plasma
cell
migrat
bone
marrow
small
portion
plasma
cell
resid
lymphoid
organ
often
shortliv
mice
day
boost
immun
ovalbumin
antigenspecif
plasma
cell
migrat
secondari
lymphoid
organ
bone
marrow
particular
bone
marrow
plasma
cell
longliv
thu
suitabl
maintain
antibodi
level
serum
extend
period
play
signific
role
pathogen
neutral
humor
immun
respons
number
clone
found
vhh
librari
gener
vaccin
infect
camel
clone
much
higher
compar
nonvaccin
infect
camel
clone
suggest
vaccin
challeng
protocol
use
studi
major
impact
frequenc
b
cell
detect
bone
marrow
camelid
speci
natur
occur
hcab
antibodi
contain
long
sequenc
allow
interact
uniqu
even
recess
epitop
may
recogn
convent
antibodi
identifi
merscovneutr
vhh
bound
rbd
spike
protein
high
affin
neutral
merscov
infect
picomolar
concentr
show
neutral
capac
concentr
pm
prnt
make
potent
potent
mab
describ
thu
far
howev
direct
comparison
differ
antibodi
would
requir
determin
exact
differ
vitro
competit
spike
protein
bind
assay
show
four
vhh
compet
bind
overlap
epitop
rbd
partial
overlap
interfac
bind
assay
use
variant
recombin
spike
protein
reveal
four
vhh
bound
wildtyp
spike
protein
protein
amino
acid
neg
charg
residu
surfac
rbd
interact
three
posit
charg
residu
outer
surfac
indic
four
vhh
prevent
viru
attach
entri
given
critic
role
amino
acid
interact
viral
escap
mutant
without
loss
fit
less
like
develop
could
reason
identifi
escap
variant
vitro
howev
structur
studi
need
pinpoint
rbdvhh
contact
residu
involv
next
produc
four
vhh
hcab
show
threefold
enhanc
merscovneutr
capac
comparison
monomer
vhh
vitro
prnt
pm
contrast
mice
prophylact
treat
fulli
protect
weight
loss
death
upon
challeng
live
viru
infecti
viru
detect
lung
mice
protect
correl
presenc
sustain
high
level
sera
mice
addit
vivo
studi
test
mab
merscov
show
reduc
merscov
replic
two
four
log
reduct
lung
viru
titer
complet
protect
higher
dose
use
per
mous
high
level
neutral
activ
prnt
pm
could
due
differ
antigen
recognit
pattern
camelid
hcab
recent
studi
also
reveal
import
long
sequenc
bovin
antibodi
rais
hiv
crossneutr
differ
viral
serotyp
therapeut
efficaci
still
need
evalu
given
limit
therapeut
efficaci
mab
acut
respiratori
infect
respiratori
syncyti
viru
human
prophylact
administr
antibodi
may
also
prefer
contain
outbreak
merscov
apart
direct
neutral
antibodi
may
also
play
role
mediat
effector
function
complementdepend
cytotox
antibodydepend
cellmedi
cytotox
fc
domain
human
limit
effector
function
vivo
suggest
observ
protect
mice
could
mainli
due
neutral
activ
therefor
addit
studi
need
evalu
whether
potenc
may
increas
replac
fc
fc
combin
antibodi
target
differ
epitop
summari
identifi
character
potent
hcab
neutral
merscov
vitro
vivo
high
affin
vivo
stabil
efficaci
hcab
may
use
prophylaxi
merscov
one
femal
one
male
healthi
dromedari
camel
camelu
dromedariu
neg
antibodi
merscov
modifi
vaccinia
viru
ankara
mva
obtain
canari
island
hous
biosecur
level
facil
centr
de
recerca
en
sanitat
anim
cresa
describ
previous
experiment
procedur
approv
local
ethic
committe
autonom
univers
barcelona
number
anim
immun
twice
interv
plaqueform
unit
mva
via
nostril
intramuscularli
neck
anim
second
immun
anim
anesthet
midazolam
mgml
inocul
tcid
merscov
ml
phosphatebuff
salin
pb
intranas
nostril
use
laryngotrach
mucos
atom
devic
blood
sampl
taken
differ
dpi
day
inocul
anim
anesthet
femor
bone
marrow
sampl
cm
collect
next
epiphysi
place
tube
contain
ml
icecold
fetal
calf
serum
specimen
gentli
crush
tip
homog
nize
slow
pipet
incub
ice
dimethyl
sulfoxid
mix
tube
prepar
dispens
cryovial
discard
debri
slur
store
recombin
fusion
protein
produc
describ
previous
briefli
plasmid
encod
merscov
merscov
rbdfc
gener
ligat
fragment
encod
subunit
genbank
access
number
residu
rbd
residu
termin
fragment
encod
fc
domain
human
pcagg
express
vector
plasmid
encod
variant
singl
amino
acid
substitut
gener
sitedirect
mutagenesi
fusion
protein
express
transfect
express
plasmid
human
embryon
kidney
hek
american
type
cultur
collect
cell
affinitypurifi
cultur
supernat
use
protein
asepharos
bead
ge
healthcar
merscovspecif
antibodi
titer
measur
elisa
first
plate
coat
merscov
merscov
rbd
protein
pb
ph
incub
overnight
well
wash
three
time
pb
block
normal
goat
serum
pb
incub
min
dromedari
camel
sera
vhh
serial
dilut
pb
ad
per
well
plate
incub
hour
next
plate
wash
three
time
pb
contain
tween
pbst
incub
biotinconjug
goat
antillama
antibodi
abcor
mous
antihistidin
antibodi
thermo
fisher
scientif
hour
three
wash
pbst
plate
incub
streptavidin
horseradish
peroxidas
hrp
dako
goat
antimous
hrp
dako
hour
incub
plate
wash
three
time
pbst
incub
room
temperatur
min
presenc
substrat
ebiosci
reaction
stop
h
sigma
absorb
sampl
read
nm
elisa
reader
tecan
infinit
rna
isol
cryopreserv
bone
marrow
cell
remov
freezer
transfer
water
bath
thaw
cell
suspens
quickli
transfer
ml
icecold
rpmi
lonza
medium
cell
count
cell
transfer
new
ribonucleas
rnase
free
falcon
tube
centrifug
room
temperatur
min
supernat
complet
remov
cell
subsequ
lyse
ml
trizol
reagent
life
technolog
ml
rnasefre
chloroform
life
technolog
mixtur
vortex
incub
min
room
temperatur
follow
centrifug
rpm
min
aqueou
phase
transfer
new
tube
subsequ
rna
isol
use
rneasi
minelut
cleanup
kit
qiagen
accord
manufactur
protocol
total
rna
quantifi
nm
use
nanodrop
qualiti
isol
rna
sampl
determin
measur
ratio
cdna
synthes
total
rna
use
firststrand
cdna
synthesi
kit
life
technolog
reaction
mix
rna
deoxynucleosid
triphosph
dntp
mm
random
hexam
mm
promega
distil
water
dh
ad
microvi
mixtur
incub
min
min
next
revers
transcriptas
mix
contain
superscript
iii
reaction
buffer
dithiothreitol
mm
rnase
inhibitor
superscript
iii
revers
transcriptas
life
technolog
ad
microvi
incub
min
min
min
cdna
store
pcr
amplif
amplif
vhh
perform
use
nest
pcr
approach
adapt
use
highfidel
dna
polymeras
pfuultra
ii
fusion
hs
dna
polymeras
stratagen
first
pcr
mix
reaction
volum
consist
pfuultra
ii
fusion
hs
dna
polymeras
buffer
dntp
mm
genespecif
forward
primer
mm
genespecif
revers
primer
mm
pfuultra
ii
fusion
hs
dna
polymeras
dh
cdna
pcr
amplif
perform
thermocycl
follow
protocol
initi
denatur
min
follow
cycl
min
final
extens
min
first
pcr
gener
two
amplifi
product
heavi
chain
convent
antibodi
bp
vhh
heavi
chain
bp
fig
amplifi
vhh
amplicon
bp
purifi
agaros
gel
use
qiaquick
gel
extract
kit
qiagen
accord
manufactur
instruct
product
subject
second
round
pcr
amplif
use
vhh
inner
primer
contain
restrict
site
clone
forward
eco
revers
pst
pcr
amplif
continu
cycl
amplicon
purifi
qiaquick
pcr
purif
kit
qiagen
digest
use
eco
pst
vector
genbank
access
number
digest
enzym
dephosphoryl
use
alkalin
phosphatas
new
england
biolab
vhh
amplicon
ligat
use
ratio
ng
vector
ng
vhh
molar
ratio
next
use
e
coli
strain
prepar
use
mix
go
e
coli
transform
kit
buffer
set
zymo
research
transform
accord
manufactur
instruct
transform
cell
directli
plate
onto
ampicillin
nutrient
agar
plate
follow
day
insert
vhh
vector
confirm
randomli
pick
clone
screen
pcr
insert
sanger
sequenc
describ
sequenc
insert
coloni
pcr
perform
use
pfuultra
ii
fusion
hs
dna
polymeras
agil
technolog
primer
giii
follow
condit
initi
denatur
min
follow
cycl
final
extens
min
amplicon
gelpurifi
sequenc
direct
use
bigdy
termin
cycl
sequenc
kit
abi
prism
genet
analyz
appli
biosystem
obtain
sequenc
assembl
align
use
clc
genom
workbench
clc
bio
supplementari
materi
articl
avail
http
advancessciencemagorgcgi
supplementari
materi
method
fig
direct
clone
express
vhh
fig
vhh
block
interact
protein
merscov
entri
receptor
tabl
characterist
merscovspecif
vhh
tabl
list
antibodi
use
studi
refer
